The role of the UConn/UConn Health’s Stem Cell Research Oversight (SCRO) Committee is to ensure that human embryonic stem cell (hESC) and human induced pluripotent stem cell (iPSC) research is well-justified and that inappropriate and/or unethical research is not conducted. Its mandate is to provide oversight of ethical issues related to the derivation and research use of human stem cell lines at all schools, colleges, campuses, and research arms of the UConn/UConn Health regardless of the source of funding, and to review all proposals from UConn/UConn Health investigators funded by the State of Connecticut’s Regenerative Medicine Research Fund. Review by the SCRO committee supplements but does not replace the usual reviews for compliance with federal, state, and local regulations (e.g., reviews by Institutional Animal Care and Use Committees (IACUC), Institutional Review Boards (IRB), Institutional Biological Safety Committees (IBC), etc.).
SCRO approval is required prior to any of the following:
- All research involving human embryonic stem cells (hESCs) (SCRO approval is required by the State of Connecticut and University policy.)
- In vitro human induced pluripotent stem cell (hiPSC) research involving the generation of gametes, embryos, or other totipotent cells (SCRO approval is required by University policy.)
- In vivo research involving introduction of human induced pluripotent stem cells (hiPSC) directly into prenatal animals or into the central nervous system of post-natal animals or elsewhere in the animal where cells could potentially enter the central nervous system (SCRO approval is required by University policy.)
- Stem cell research project funded by the State of Connecticut through the Connecticut Bioscience Innovation Fund, including those that do not use human embryonic stem cells (SCRO approval is required by the State of Connecticut.)